FDA has granted approval to Orchard Therapeutics for Lenmeldy (atidarsagene autotemcel), which marks the first FDA-approved gene therapy for treating children with juvenile metachromatic leukodystrophy (MLD) in the United States. Following the approval, AGC Biologics announced that it will be manufacturing the therapy at its Milan, Italy, site. Source: Biopharm International 19/3/2024